TrialTrials2009

Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy.

ACT Trial InvestigatorsPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.